BioMarin Pharma (BMRN) Tops Q3 EPS by 20c

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.12, $0.20 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $776 million versus the consensus estimate of $782.3 million.

GUIDANCE:

BioMarin Pharma sees FY2025 EPS of $4.40-$4.55, versus the consensus of $3.34. BioMarin Pharma sees FY2025 revenue of $3.15-3.2 billion, versus the consensus of $3.17 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
• Genuine Parts Said To Receive O’reilly Interest For Auto Unit - Bloomberg
• Jefferson Capital (JCAP) files $100M mixed shelf